title: Ovarian function during and after treatment with the new progestagen Org 30659.
abstract: OBJECTIVE
  To evaluate ovarian function during 21 days of oral administration of different doses of Org 30659, a novel selective progestagenic steroid.
  
  
  METHODS
  Randomized, double-blind, dose-finding study.
  
  
  METHODS
  Three centers in Austria, Sweden, and the United Kingdom.
  
  
  METHODS
  Eighty-one healthy women 19-40 years of age with regular ovulatory cycles.
  
  
  METHODS
  Daily oral administration of 0.060, 0.120, 0.180, or 0.240 mg of Org 30659, or 0.075 mg desogestrel (reference group), for 21 days.
  
  
  METHODS
  Once-daily measurements of follicular diameter and 17-beta estradiol, progesterone, FSH, and LH levels.
  
  
  RESULTS
  Daily treatment with Org 30659 for 21 days caused dose-dependent suppression of ovarian activity. No ovulation was observed in any study group. On average, ovulation returned 16.5 to 22.1 days after treatment. The effects of desogestrel, 0.075 mg, were similar to those of 0.060 and 0.120 mg of Org 30659. All doses were well tolerated, as shown by the type of side effects that occurred, the absence of an effect on physical and laboratory findings, and the low rate of study discontinuation.
  
  
  CONCLUSIONS
  Daily oral administration of 0.060-0.240 mg of Org 30659 suppresses ovarian function to a level sufficient to inhibit ovulation. This effect is dose-dependent, and the suppressive effect is readily reversible at all doses tested. Org 30659 can thus be safely administered orally for 21 days to healthy female volunteers in a dosage of 0.060 mg/d to 0.240 mg/d.
authors: University of Vienna, General Hospital, Department of Obstetrics and Gynaecology, Vienna, Austria.
authors: A
authors: A
authors: Obruca
authors: T
authors: T
authors: Korver
authors: J
authors: J
authors: Huber
authors: S R
authors: SR
authors: Killick
authors: B
authors: B
authors: Landgren
authors: M J
authors: MJ
authors: Struijs
mesh_terms: D000328:Adult; D017135:Desogestrel / Q000009:adverse effects / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology*; D010053:Ovary / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000502:physiology*; D010060:Ovulation / Q000187:drug effects; D045167:Progesterone Congeners / Q000009:adverse effects / Q000494:pharmacology; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D014463:Ultrasonography
chemical_list: D045167:Progesterone Congeners; D011372:Progestins; D017135:Desogestrel; D009640:Norethindrone; C097629:Org 30659